Shares of Stevanato Group S.p.A. (STVN) Have Risen Above Previous 52-Week High

IBN Spotlights
Friday, September 24, 2021 at 3:51pm UTC

Shares of Stevanato Group S.p.A. (NYSE:STVN) traded at a new 52-week high today of $29.18. This new high was reached on below average trading volume as 92,000 shares traded hands, while the average 30-day volume is approximately 741,000 shares.

Stevanato Group S.p.A. (NYSE:STVN) is currently priced 37.9% above its average consensus analyst price target of $17.92.

Stevanato Group SPA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages.

In the past 52 weeks, Stevanato Group S.p.A. share prices are bracketed by a low of $16.61 and a high of $29.18 and is now at $28.85, 74% above that low price.

Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts

To stay connected with our complimentary IBN Spotlights, please visit

About IBN (InvestorBrandNetwork)

IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.

For more information on IBN, please visit

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: